Skip to content

Multicenter Trial of Daily Chlorhexidine Bathing to Reduce Nosocomial Infections

Multicenter Evaluation of The Effectiveness of Source Control With Daily Chlorhexidine Skin Preparation in Reducing Nosocomial Infections Including MRSA and VRE

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00502476
Acronym
CBET
Enrollment
14000
Registered
2007-07-17
Start date
2007-08-31
Completion date
2009-09-30
Last updated
2007-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MRSA Colonization, MRSA Infection, Nosocomial Bacteremia, VRE Colonization, VRE Infection

Keywords

MRSA, VRE, BSI

Brief summary

To determine if daily bathing with chlorhexidine impregnated washcloths will reduce the incidence of MRSA and VRE within an Intensive Care Unit (ICU) or ward setting.

Detailed description

This is a cluster randomized, crossover-controlled trial with wards as the units of randomization. The trial will predominantly take place in ICU's but may include any acute care ward that has active surveillance for MRSA and or VRE in place (i.e., Bone Marrow transplant units, Oncology wards, etc.) Units will be randomly assigned to utilize two bathing routines in a random order. Each bathing routine will be utilized on all admitted patients to the unit for a six month study period for a total study duration of 12 months. The two bathing routines will include either the use of the Comfort® Bath Washcloth System (control) or the use of 2% Chlorhexidine Gluconate Cloth. Randomized units will either start with 2% Chlorhexidine Gluconate Cloth for six months and then switch to Comfort™ Bath Washcloth for the remaining six month period or the reverse order. Data collection will include all surveillance and clinical cultures for MRSA and or VRE and all bloodstream infections.

Interventions

PROCEDUREBathing with Chlorhexidine Impregnated Washcloths

Sponsors

Centers for Disease Control and Prevention
CollaboratorFED
Sage Products, Inc.
CollaboratorINDUSTRY
Hunter Holmes Mcguire Veteran Affairs Medical Center
Lead SponsorFED

Study design

Observational model
DEFINED_POPULATION
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients admitted to study units during the proposed study interval are eligible for inclusion in the study

Exclusion criteria

* Patients with known allergies to chlorhexidine gluconate or any other ingredients in the product * Patients with burns that include a high percentage of disrupted body surface area * Use in patients undergoing lumbar punctures or contact with the meninges * Patients with large open skin wounds; and * Children less than 18 years old

Countries

United States

Contacts

Primary ContactMichael W Climo, MD
michael.climo@va.gov(804) 675-5018
Backup ContactEdward S Wong, MD
edward.wong@va.gov(804) 675-6792

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026